tbuckley/cabot-search huggingface dataset:
NON-FLUORESCENT MICROSPORUM AUDOUINI AND CANIS INFECTIONS OF THE SCALP
Authors: MARTIN BEARE, JACQUELINE WALKER
Journal: British Journal of Dermatology (1955)

Journal Article NON‐FLUORESCENT MICROSPORUM AUDOUINI AND CANIS INFECTIONS OF THE SCALP Get access MARTIN BEARE, M.D., M.R.C.P., MARTIN BEARE, M.D., M.R.C.P. Assistant Physician, Skin Department, Royal Victoria Hospital, Belfast; Assistant Dermatologist, Royal Belfast Hospital for Sick Children Search for other works by this author on: Oxford Academic Google Scholar JACQUELINE WALKER, Ph.D. JACQUELINE WALKER, Ph.D. Mycological Reference Laboratory, Public Health Laboratory Service, London School of Hygiene and Tropical Medicine Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 67, Issue 3, 1 March 1955, Pages 101–104, https://doi.org/10.1111/j.1365-2133.1955.tb12699.x Published: 01 March 1955
Evaluating computerised health information systems: We are still getting information technology wrong
Authors: M. G Evans
Journal: BMJ (2003)

EDITOR—Littlejohns et al evaluated computerised health information systems.1 After his departure from the Department of Health, Lord Hunt said that his greatest fear was that “we won't get the doctors on board.” Like most clinicians and other “hands on” NHS staff (I suspect), I favour a bottom up approach to information technology in the NHS.

If Lord Hunt …
PULSUS PARADOXUS IN PERICARDITIS WITH EFFUSION.
Authors: W. J. CALVERT
Journal: JAMA (1907)

seldom the outcome of the stammering mind of Mr. Ready-tohalt.The armed neutrality which promises operation if the need arises was, and is, the orthodox plan and has much to say for itself; but as Carlyle remarks, "The two internecine plans collapsing into one, that is the clearly fatal method."
Abstract 841: CCL2 and interleukin-6 regulate EMT-mediated chemo-resistance in prostate cancer
Authors: Chunlin Zou, Yi Lu, Atsushi Mizokami, Evan T. Keller, Kenneth J. Pienta, Jian Zhang
Journal: Cancer Research (2012)

Abstract Prostate cancer (PCa) is one of the most common cancers and the second leading cause of cancer-related death in western countries. In China, the incidence has increased, unexpectedly and sharply, for the past 20 years. Chemo-resistance, in various types of tumor including PCa, is one of the critical problems in cancer therapy. In PCa, for example, the resistance to taxanes (DTX) accounts for tumor relapse and progression resulting in skeletal metastasis and high mortality. Epithelial-mesenchymal transition (EMT) has been suggested as a key process that dominates chemo-resistance through unknown mechanisms. In the current study, we reported that CCL2 and interleukin-6 (IL-6) serve as key molecules in EMT-mediated chemo-resistance in PCa cells using previously established paclitaxel-resistant cells, DU145-TxR and PC-3-TxR. Parental DU145 and PC-3 cells were used as controls. We observed that DU145-TxR and PC-3-TxR cells produced significantly higher amount of CCL2 and IL-6 compared to their parental cells, determined by cytokine array. In addition, DU145-TxR and PC-3-TxR cells demonstrated EMT phenotypes including hall maker changes in E-cadherin and Vimentin expression and transcriptional factor (Snail, ZEB1, and Slug) alterations. These changes were reversed partially by adding neutralizing antibodies against either CCL2 or interleukin-6. Interestingly, synergistic effects were observed by adding both reagents. Finally DU145-TxR, PC-3-TxR, or their parental cells were implanted into SCID mice and the mice were given DTX (10mg/kg, biweekly) and tumor growth was monitored for 4 weeks. Both DU145-TxR and PC-3-TxR tumors grew faster than the parental tumors. Tumor tissues were collected and total RNAs were isolated. Levels of CCL2 expression in these tumors were significantly higher in DU145-TxR and PC-3-TxR tumors. IHC analysis confirmed corresponding staining of EMT markers such as E-cadherin and Vimentin expression. Together we concluded that CCL2 and IL-6 regulates EMT-mediated chemo-resistance in prostate cancer. These results are of high impact of human prostate cancer chemotherapy. Supported by U.S. Department of Defense PC061231 (J. Zhang), National Natural Sciences Foundation Key Project (81130046, J. Zhang) and National Natural Science Foundation Project (81171993, Y. Lu). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 841. doi:1538-7445.AM2012-841
Persistent immunity after therapeutic vaccination targeting HER2/neu correlated with post-vaccination magnitude of interferon gamma Elispot responses
Authors: John B Liao, Jessica L Reichow, Doreen M Higgins, Jennifer S Childs, Lupe G Salazar, Mary L Disis
Journal: Journal for ImmunoTherapy of Cancer (2014)

Meeting abstracts As therapeutic vaccination approaches are explored for cancer therapy, there is a need to identify milestones that can predict the successful induction of sustained immunity. We examined whether the magnitude of immune responses seen prior to vaccination or at the completion of a
Cytoskeletal protein 4.1R negatively regulates T-cell activation by inhibiting the phosphorylation of LAT
Authors: Qiaozhen Kang, Yu Yu, Xinhong Pei, Richard Hughes, Susanne Heck, Xihui Zhang, Xinhua Guo, Gregory Halverson, Narla Mohandas, Xiuli An
Journal: Blood (2009)
Transmembranal Potentials from the Human Heart
Authors: J. WALTER WOODBURY, JOHN LEE, ALLAN J. BRADY, K. ALVIN MERENDINO
Journal: Circulation Research (1957)

Intracellular action potentials from human ventricular muscle have been recorded with the flexibly mounted ultramicroelectrode. The complete record, correlated with the lead I electrocardiogram, is presented. The size, duration and shape of the human potentials closely resemble those previously recorded from lower animals.
Renal Circulation and Cardiac Output in "Low-output" Heart Failure and in Myxoedema
Authors: C. E. Davies, J. Mackinnon, M. M. Platts
Journal: BMJ (1952)

VITAMIN B12 IN PERNICIOUS ANAEMIA mrnm 595 (Nos.4, 7, 8) had initial sore tongue.These symptoms had complete relief.One patient (No. 15) had a severe stomatitis, which had resisted many forms of treatment but improved rapidly after the injection.Only one patient (No. 1) developed slight paraesthesiae while under observa- tion, at a time when the blood showed evidence of relapse eight months after the injection.The symptoms disappeared after the second injection and did not return within 49 weeks.SummaryFifteen patients with untreated pernicious anaemia were given a single parenteral dose of 1 mg. of vitamin B12 and followed until relapse.The clinical state, blood, and marrow remained normal in one case for as long as 358 days after such a dose, but the earliest relapse occurred in 128 days, excluding one case with hepatic insufficiency where it occurred at 81 days.The marrow showed minor signs of reversion to megaloblastic haemopoiesis 40-50 days before there was any sign of relapse clinically or in the blood.No untoward neurological.orother clinical symptoms were encountered in any patient with initially uncom- plicated pernicious anaemia, but the one patient in the series with subacute combined degeneration had to have intensive treatment resumed at the sixth week because of neurological deterioration.While of theoretical and practical interest, these find- ings do not justify, without further trials, the routine treatment of pernicious anaemia by 1 mg.doses of vitamin B12 at long intervals.We would .
Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.
Authors: M H Giaffer, A Clark, C D Holdsworth
Journal: Gut (1992)

Saccharomyces cerevisiae (baker's yeast) may play an important part in the pathogenesis of Crohn's disease. Because of this the levels of IgG and IgA antibodies against three S cerevisiae strains (NCYC 77, NCYC 79, and NCYC 1108) were assayed in 49 patients with Crohn's disease, 43 with ulcerative colitis, 14 with coeliac disease, and 21 healthy controls. Coded serum samples were tested by ELISA. Similar antibody patterns to all three strains were found. IgG and IgA antibody levels were significantly raised in patients with Crohn's disease compared with healthy controls (p < 0.001 and p < 0.0001 respectively) and with ulcerative colitis patients (p < 0.0001 and p < 0.0006 respectively). Raised IgA, but not IgG, yeast antibody levels were found in two patients with Crohn's disease who were intolerant to yeast, but these values were similar to those in other patients without yeast intolerance. In ulcerative colitis, both IgG and IgA levels were similar to normal controls. Patients with small bowel Crohn's disease had significantly higher IgG antibody levels than those with colonic disease (p < 0.01). High levels of IgG, but not IgA, antibody were present in patients with coeliac disease, the antibody responses being indistinguishable from those found in Crohn's disease. It is concluded that the presence of IgG antibody to S cerevisiae is characteristic but not specific to Crohn's disease. Although raised IgA antibody levels are more frequently found in Crohn's disease, their pathogenic importance remains to be established.
Heart Valve Disorders and Appetite-Suppressant Drugs
Authors: Hershel Jick
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intra-arterial temazepam.
Authors: R. N. Scott, J. Going, K. R. Woodburn, D. G. Gilmour, D. B. Reid, D. P. Leiberman, B. Maraj, J. G. Pollock
Journal: BMJ (1992)

Intra-arterial temazepam EDITOR,-We write to draw attention to compli- cations resulting from the new "abuse resistant"' formulation of temazepam capsules.In the past six months we-have seen 15 injecting drug misusers (13 men, two women, aged 19-35) with severe complications of intra-arterial injection (10 femoral, five brachial) of "solid" gel temazepam.Patients prepared the capsules by removing the soft gelatin shell, boiling the "solid" gel centre with water in a spoon, and injecting the warm suspension.All described instant pain in the region supplied by the injected artery.
PSA Thresholds for Prostate Cancer Detection
Authors: Richard M. Hoffman
Journal: JAMA (1997)

<h3>To the Editor.</h3> —Dr Catalona and colleagues,<sup>1</sup>reporting on a prospective study using PSA in detecting prostate cancer, concluded that "[f]ree serum PSA measurements may reduce the number of additional biopsies required by the lower PSA cutoff" in men with PSAs in the range of 2.6 to 4.0 ng/mL. One of us<sup>2</sup>previously analyzed data from a study of Gann et al<sup>3</sup>showing that their PSA stratum of 2.1 to 4.0 ng/mL provided no information to increase or decrease the probability of aggressive prostate cancer because the 95% confidence intervals of the likelihood ratio for this stratum included 1.0. Unfortunately, the study by Catalona et al did not report the usual operating characteristics for screening and diagnostic tests, ie, sensitivity, specificity, likelihood ratios, and the area under the receiver operating characteristic curve for using the percentage of free PSA. Of the 332 men described, 317 had free PSA measurements, and 72 of these men (23%) had cancer and
FURTHER CHARACTERIZATION OF THE ADENOVIRUS ERYTHROCYTE RECEPTOR-MODIFYING FACTOR
Authors: Julius A. Kasel, Wallace P. Rowe, John L. Nemes
Journal: The Journal of Experimental Medicine (1961)

Agglutinability of human erythrocytes for 3 hemagglutinating adenoviruses was markedly reduced by pretreatment of red cells with a factor present in tissue cultures which had been infected with adenovirus types 1, 2,4, or 15. The factor responsible for erythrocyte receptor modification was non-dialyzable and unaffected by the action of ribonuclease, desoxyribonuclease, trypsin, chymotrypsin, or ether. The factor was smaller, more thermostable, and separable from the infectious virus. Erythrocyte receptor modification was found to be a function of time and temperature. Titers of erythrocyte receptor-modifying activity were not diminished by successive exposures to fresh erythrocytes. Erythrocytes treated with erythrocyte receptor-modifying factor suspensions failed to significantly adsorb test virus hemagglutinin. Inhibition of erythrocyte receptor modifying-activity of the adenovirus suspensions by rabbit antiserum was type-specific.
Superficial blood flow following photodynamic therapy of malignant non-melanoma skin tumours measured by laser Doppler perfusion imaging
Authors: I. WANG, S. ANDERSSON-ENGELS, G.E. NILSSON, K. WARDELL, K. SVANBERG
Journal: British Journal of Dermatology (1997)

Laser Doppler perfusion imaging offers a new modality for in vivo monitoring of the superficial blood perfusion in biological tissue. In this study, the superficial blood perfusion of malignant nonmelanoma skin tumours and the surrounding normal skin was measured in conjunction with photodynamic therapy (PDT) using topical ò–aminolaevulinic acid (ALA)–induced protoporphyrin IX as a photosensitizer. The results clearly show that, in contradiction to PDT with the intravenously administered photosensitizer photofrin. no direct vascular damage can be seen. With the topical sensitization the blood perfusion is increased immediately after the treatment irradiation. The increased blood flow is seen up to a week after treatment, in a similiar way as for an inflammatory reaction. Despite this, all basal cell carcinoma and squamous cell carcinoma in situ lesions in this study healed without any sign of residual tumour after the treatment, suggesting an efficient direct tumour cell destruction induced by PDT.
Prophylaxis after Sexual Exposure to HIV
Authors: Steven D. Pinkerton
Journal: Annals of Internal Medicine (1998)

Letters15 October 1998Prophylaxis after Sexual Exposure to HIVSteven D. Pinkerton, PhD and David R. Holtgrave, PhDSteven D. Pinkerton, PhDMedical College of Wisconsin; Madison, WI 53226Search for more papers by this author and David R. Holtgrave, PhDMedical College of Wisconsin; Madison, WI 53226Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-8-199810150-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Drs. Katz and Gerberding [1] recommend offering patients postexposure prophylaxis with antiretroviral drugs to prevent HIV infection after risky sexual activities. As they note, the availability of this prophylaxis could have profound behavioral, social, and economic consequences. In particular, the economic impact of postexposure prophylaxis could be substantial. The cost of a 4-week course of postexposure prophylaxis, including laboratory work and clinic visits, is approximately $1100 [2]. These costs must, of course, be balanced against the tremendous costs associated with failing to prevent HIV infection. But they must also be balanced against the costs of alternative strategies ...References1. Katz MH, Gerberding JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med. 1998; 128:306-12. Google Scholar2. Li RW, Wong JB. Postexposure treatment of HIV [Letter]. N Engl J Med. 1997; 337:499-500. Google Scholar3. Pinkerton SD, Holtgrave DR, Bloom FR. Postexposure treatment of HIV [Letter]. N Engl J Med. 1997; 337:500-1. Google Scholar4. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of postexposure prophylaxis following sexual exposure to HIV. AIDS. 1998; 12:1067-78. Google Scholar5. Holtgrave DR, Pinkerton SD. The economics of HIV primary prevention. In: Peterson JL, DiClemente RJ, eds. Handbook of HIV Prevention. New York: Plenum Pr; [In press]. Google Scholar Author, Article, and Disclosure InformationAffiliations: Medical College of Wisconsin; Madison, WI 53226 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United StatesPreventable Methotrexate Toxicity ADRs Related to Ophthalmic Agents; Ophthalmic Adverse Effects Caused by Systemic Drugs ADRs with Antiretroviral Prophylaxis ADRS with Antimalarial ProphylaxisCombination Antiretroviral Therapies for HIV 15 October 1998Volume 129, Issue 8Page: 671KeywordsAntiretroviralsBehavioral economicsDrugsHIVHIV infectionsHIV preventionHuman sexual behaviorPostexposure prophylaxisProphylaxisResearch laboratories Issue Published: 15 October 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Femoral Nerve Entrapment Secondary to a Heparin Hematoma
Authors: GEORGE P. SUSENS
Journal: Annals of Internal Medicine (1968)

Femoral nerve paralysis secondary to heparin hematoma in or on the iliacus muscle occurred in two patients. After consideration of the pertinent anatomy, clinical manifestations, and possible pathogenesis of this syndrome, it is suggested that the subcutaneous injection of heparin may contribute to its production.
Health Care in Cambodian Refugee Camps
Authors: TIMOTHY D. MASTRO
Journal: Annals of Internal Medicine (1987)

Letters and Corrections1 January 1987Health Care in Cambodian Refugee CampsTIMOTHY D. MASTRO, M.D.TIMOTHY D. MASTRO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-106-1-173_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: As former medical coordinator (1984-85) of the United Nations Border Relief Operation on the Thai-Cambodian border, I read Soffer and Wilde's recent article (1) on medicine in Cambodian refugee camps with great interest. One technical issue warrants correction. The 1985 budget for health and sanitation was US $27.00 per person. The figure of US $6.70 quoted by the authors reflects the per-person pharmacy supply utilization.Although I agree with the authors' conclusion that refugee camp medicine may be rewarding for many in the medical profession, it should be borne in mind that curative medical care should not...References1. SOFFER A and WILDE H. Medicine in Cambodian refugee camps. Ann Intern Med. 1986;105:618-21. LinkGoogle Scholar2. NIEBERG P, ALLEGRA D, and GRABE M. The evolution of a refugee-assistance operation: who is needed—and when? In: ALLEGRA DT, NIEBERG P, GRABE M, eds. Emergency Refugee Health-Care: A Chronicle of Experience in the Khmer Assistance Operation 1979-1980. Atlanta, Georgia: Centers for Disease Control; 1984:93-8. Google Scholar3. SMILKSTEIN G. Refugees in Thailand and short-term medical aid. JAMA. 1981;245:1052-4. CrossrefMedlineGoogle Scholar4. . Handbook for Emergencies: Field Operations. Geneva: World Health Organization; 1982. (Available from U.N. High Commissioner for Refugees, Palais des Nations; CH-1211 Geneva 10, Switzerland.) Google Scholar5. SIMMONDS S, VAUGHAN P, and GUNN S. Refugee Community Health Care. Oxford: Oxford University Press; 1983. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: TIMOTHY D. MASTRO, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Cradle of the New Humanitarian System? International Work and European Volunteers at the Cambodian Border Camps, 1979–1993More on Medicine in Refugee CampsTHOMAS C. JONES, M.D. 1 January 1987Volume 106, Issue 1 Page: 173-174 Keywords Cyclic adenosine monophosphate Health care Health care utilization Sanitation ePublished: 1 December 2008 Issue Published: 1 January 1987 PDF downloadLoading ...
OSTEO MENTHESIS.Read in the Section of Surgery and Anatomy at the Forty-second Annual Meeting of the American Medical Association, held at Washington, D. C., May, 1891.
Authors: B. MERRILL RICKETTS
Journal: JAMA (1891)

I wish to call your attention to the subject of osteo penthesis, the subject of which I made brief mention at the last meeting of the New York State Medical Association, which convened in New York City. Dealing with bone tissue has been one of the most interesting subjects to me, and I may say to surgeons in general. The three principal points which I wish to bring out in this paper are as follows: First: How and when may bones be restored? Second: Should fragments of the bone be permanently removed except in case of amputation? Third: Should not exploratory incisions be made in cases of fracture of bones where doubt exists as to their character? I cannot do better, after making brief mention of these three interesting features, than to report the observations I have made in experimenting with the lower animals. In the first case: How and
Response to Letter Regarding Article, “Mitochondrial DNA Damage Can Promote Atherosclerosis Independently of Reactive Oxygen Species Through Effects on Smooth Muscle Cells and Monocytes and Correlates With Higher-Risk Plaques in Humans”
Authors: Emma Yu, Patrick A. Calvert, John R. Mercer, James Harrison, Lauren Baker, Nichola L. Figg, Sheetal Kumar, Julie J. Wang, Liam A. Hurst, Daniel R Obaid, Angela Logan, Nick E.J. West, Murray C.H. Clarke, Antonio Vidal-Puig, Michael P. Murphy, Martin R. Bennett
Journal: Circulation (2014)
Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
Authors: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, Markus A. Kuczyk, Axel S. Merseburger, Maria José Ribal, Amir Sherif, J. Alfred Witjes
Journal: European Urology (2011)